A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

This study has been terminated.
(Sponsor could no longer support; enrollment stopped August 2008.)
Sponsor:
Information provided by (Responsible Party):
Cortice Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT00479635
First received: May 24, 2007
Last updated: January 9, 2014
Last verified: January 2014
  Purpose

The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.


Condition Intervention Phase
Prostate Cancer
Drug: TPI 287
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Taxane Regimen

Resource links provided by NLM:


Further study details as provided by Cortice Biosciences, Inc.:

Primary Outcome Measures:
  • Response [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to progression [ Time Frame: 15 months ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: Continuous ] [ Designated as safety issue: Yes ]

Enrollment: 26
Study Start Date: January 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TPI 287 Drug: TPI 287
160 mg/m2 every three weeks for six cycles
Drug: TPI 287
160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.

Detailed Description:

This is an open-label, multi-center, 2-stage Simon design, Phase 2 study of TPI 287 in patients with metastatic, hormone-refractory prostate cancer. All patients must have received prior taxane therapy. Up to 80 patients will be enrolled and stratified based on duration of cumulative exposure to a single prior taxane regimen. A single taxane regimen is considered to he a taxane or taxane containing therapy administered on a defined schedule with no more than 2 months' interruption between treatments, and total exposure will be assessed by the number of months on that schedule.

One stratum (up to 40 patients) will consist of patients who have had over 3 months (up to a maximum of 10 months) exposure to a taxane regimen, who then have documented progression of disease (initially taxane sensitive). The second stratum (up to 40 patients) will consist of patients considered primarily resistant to taxanes who have had documented progressive disease as best response after exposure to a single taxane regimen for less than or equal to 3 months. Patients may have received prior hormonal therapy and/or bisphosphonates and may continue on these therapies.

In the first stage of the trial, 22 patients in each stratum will be treated with TPI 287 intravenously every 21 days. If 1 or fewer patients in either stratum demonstrate a response in this first stage, the trial will be discontinued for that stratum. Otherwise, an additional 18 patients in the stratum showing 2 or more responses will be enrolled in the second stage of the study. If 4 or fewer patients demonstrate a response in the total study population in either stratum from stages 1 and 2, then the drug will not be considered of interest in prostate cancer for patients as defined in that stratum.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological or cytological evidence of adenocarcinoma of the prostate and have metastatic disease.
  • Patients must have received only one prior regimen for their advanced disease. This regimen must have included a taxane.

    • First Stratum Eligibility: Patients must have advanced, metastatic prostate cancer with documented progression after receiving more than three months of treatment, up to a total of 10 months with 1 prior taxane regimen. Prior best response to treatment, and duration of response, will be recorded.
    • Second Stratum Eligibility: Patients must have advanced, metastatic prostate cancer that has progressed as best response despite three months or less of treatment with 1 prior taxane regimen.
  • Must have castrate levels of testosterone less than 50 ng/mL
  • Must have an ECOG Performance Score of 0 or 1
  • Must be age 18 or older
  • Must be able to read, understand and sign informed consent
  • Serum creatinine less than or equal to 2.0 mg/dL
  • Total bilirubin less than or equal to 2.0 mg/dL
  • SGOT/SGPT less than or equal to 3 times the ULN
  • ANC greater than or equal to 1500/UL
  • Platelet count greater than or equal to 100,000/UL Recovered from the effects of prior surgery, radiotherapy or other antineoplastic therapy.

Exclusion Criteria:

  • Active infection or with a fever greater than or equal to 38.5 degrees centigrade within 3 days of first scheduled day of dosing
  • More than one prior systemic therapy for HRPC beyond androgen-ablative therapy. Prior systemic therapy may have been administered for metastatic disease or as adjuvant therapy
  • Has received radiotherapy to greater than 30% of their active bone marrow
  • History of prior malignancy within the past 5 years except for curatively treated non-melanoma skin cancer
  • Impending fracture of a weight bearing bone
  • Known hypersensitivity to any of the components of TPI 287
  • Receiving concurrent investigational therapy or who have received investigational therapy within 30 days of study start
  • Grade 2 peripheral neuropathy
  • NYHA Class 3 or 4 congestive heart failure
  • Any medial condition that would interfere with ability to sign ICF, cooperate and participate in the study or interfere with interpretation of results
  • History of allogenic transplant
  • Know HIV or Hepatitis B or C positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00479635

Locations
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Comprehensive Cancer Center at Desert Mountain
Palm Springs, California, United States, 92262
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Missouri
Kansas City Cancer Center South
Kansas City, Missouri, United States, 64131
United States, New Jersey
St. Barnabas Medical Center
Livingston, New Jersey, United States, 07039
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Cortice Biosciences, Inc.
Investigators
Study Director: Sandra Silberman, MD, PhD SLS Oncology, LLC
  More Information

Additional Information:
No publications provided

Responsible Party: Cortice Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT00479635     History of Changes
Other Study ID Numbers: TPI 287-04
Study First Received: May 24, 2007
Last Updated: January 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cortice Biosciences, Inc.:
HRPC
TPI 287
Taxane
MDR
Hormone Refractory Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 18, 2014